Related Experiment Video
Updated: Aug 19, 2025
12:32
High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
12.2K
Potentilla bifurca flavonoids effectively improve insulin resistance
1College of Life Science, Qinghai Normal University, Xining, China. zy-3@263.net.
European Review for Medical and Pharmacological Sciences
|December 2, 2022
Summary
Potentilla bifurca compounds show promise for type 2 diabetes treatment by improving insulin resistance in fat cells. This natural compound helps regulate sugar and fat metabolism, offering a potential therapeutic avenue.
Area of Science:
- Pharmacology and Traditional Medicine
- Metabolic Disorders
- Cell Biology
Background:
- Type 2 diabetes is characterized by impaired glucose and lipid metabolism.
- Insulin resistance is a key feature of type 2 diabetes, leading to hyperglycemia.
- Potentilla bifurca is a plant with a history of traditional medicinal use.
Purpose of the Study:
- To investigate the therapeutic potential of Potentilla bifurca in managing type 2 diabetes.
- To evaluate the effects of Potentilla bifurca compounds on insulin resistance in vitro.
Main Methods:
- Utilized 3T3-L1 adipocytes to model insulin resistance.
- Administered compounds derived from Potentilla bifurca to the adipocytes.
- Assessed changes in glucose uptake, IL-6 levels, and key proteins in the IRS/PI3K/Akt pathway.
Main Results:
- Potentilla bifurca compounds significantly improved glycolipid metabolism in insulin-resistant 3T3-L1 adipocytes.
- Enhanced glucose uptake and reduced IL-6 content were observed.
- Regulation of the IRS/PI3K/Akt signaling pathway, including p-Akt/Akt, IKKβ, and p-NF-κBp65/NF-κBp65, was demonstrated.
Conclusions:
- Potentilla bifurca exhibits significant potential for treating type 2 diabetes.
- The plant's compounds effectively modulate key pathways involved in insulin resistance and glucolipid metabolism.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
259
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
259
01:23Dipeptidyl Peptidase 4 Inhibitors
230
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
230
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
234
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
234
02:59Cancer Prevention
6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.3K
01:24Glucagon-like Receptor Agonists
383
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383
01:06Oral Hypoglycemic Agents: Glinides
215
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
215